Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
About this trial
This is an interventional treatment trial for Adult Giant Cell Glioblastoma
Eligibility Criteria
Inclusion Criteria: Histologically confirmed diagnosis of 1 of the following: Glioblastoma multiforme (grade 4 astrocytoma) Gliosarcomas Other grade 4 astrocytoma variants (e.g., giant cell) Must be enrolled at least 1 week, but no more than 4 weeks, after prior biopsy or surgery Performance status - ECOG 0-2 Performance status - Karnofsky 60-100% At least 6 months Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hemoglobin ≥ 9 g/dL Total bilirubin ≤ upper limit of normal (ULN) AST no greater than 2.5 times ULN Creatinine no greater than 1.5 times ULN No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No inability to take oral medications No requirement for IV alimentation No active uncontrolled peptic ulcer disease No abnormalities of the cornea (e.g., dry eye syndrome or Sjögren's syndrome) No congenital abnormality (e.g., Fuch's dystrophy) No abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose) No abnormal corneal sensitivity test (e.g., Schirmer test or similar tear production test) No prior allergy or intolerance to dacarbazine No other active malignancy requiring treatment No other concurrent uncontrolled illness No ongoing or active infection No psychiatric illness or social situation that would preclude study compliance Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No prior chemotherapy for any brain tumor No prior temozolomide No prior radiotherapy for any brain tumor No other concurrent investigational agents More than 21 days since prior major surgery (excluding neurosurgical biopsy or brain tumor resection) No prior surgical procedures affecting absorption No concurrent combination antiretroviral therapy for HIV-positive patients No concurrent warfarin
Sites / Locations
- Mobile Infirmary Medical Center
- Mayo Clinic in Arizona
- Mayo Clinic in Florida
- Northeast Georgia Cancer Care LLC
- Rush - Copley Medical Center
- Saint Joseph Medical Center
- Graham Hospital Association
- Memorial Hospital
- Saint Anthony Memorial Hospital
- Eureka Hospital
- Galesburg Cottage Hospital
- Illinois CancerCare Galesburg
- Western Illinois Cancer Treatment Center
- Mason District Hospital
- Hopedale Medical Complex - Hospital
- Joliet Oncology-Hematology Associates Limited
- Kewanee Hospital
- Mcdonough District Hospital
- Garneau, Stewart C MD (UIA Investigator)
- Porubcin, Michael MD (UIA Investigator)
- Sharis, Christine M MD (UIA Investigator)
- Stoffel, Thomas J MD (UIA Investigator)
- Vigliotti, Antonio, P.G. M.D. (UIA Investigator)
- Bromenn Regional Medical Center
- Community Cancer Center Foundation
- Illinois CancerCare-Ottawa Clinic
- Ottawa Regional Hospital and Healthcare Center
- Pekin Cancer Treatment Center
- Pekin Hospital
- Methodist Medical Center of Illinois
- Proctor Hospital
- Illinois CancerCare-Peoria
- Illinois Oncology Research Association CCOP
- OSF Saint Francis Medical Center
- Illinois Valley Hospital
- Perry Memorial Hospital
- Saint Margaret's Hospital
- Valley Cancer Center
- Carle Clinic-Urbana Main
- Saint Anthony Memorial Health Center
- McFarland Clinic
- Constantinou, Costas L MD (UIA Investigator)
- Saint Anthony Regional Hospital
- Saint Luke's Hospital
- Cedar Rapids Oncology Association
- Mercy Hospital
- Oncology Associates at Mercy Medical Center
- Medical Oncology and Hematology Associates-West Des Moines
- Alegent Health Mercy Hospital
- Mercy Capitol
- Iowa Methodist Medical Center
- Iowa Oncology Research Association CCOP
- Medical Oncology and Hematology Associates-Des Moines
- Medical Oncology and Hematology Associates
- Mercy Medical Center - Des Moines
- Iowa Lutheran Hospital
- Community Memorial Hospital
- Burgess Memorial Hospital
- Siouxland Regional Cancer Center
- Siouxland Hematology Oncology Associates
- Mercy Medical Center-Sioux City
- Saint Luke's Regional Medical Center
- Hospital District Sixth of Harper County
- Cancer Center of Kansas - Chanute
- Cancer Center of Kansas - Dodge City
- Cancer Center of Kansas - El Dorado
- Cancer Center of Kansas - Fort Scott
- Cancer Center of Kansas-Independence
- Cancer Center of Kansas-Kingman
- Lawrence Memorial Hospital
- Cancer Center of Kansas - Newton
- Cancer Center of Kansas - Parsons
- Cancer Center of Kansas - Pratt
- Cancer Center of Kansas - Salina
- Cancer Center of Kansas - Wellington
- Associates In Womens Health
- Cancer Center of Kansas-Wichita Medical Arts Tower
- Cancer Center of Kansas - Main Office
- Via Christi Regional Medical Center
- Wesley Medical Center
- Wichita CCOP
- Cancer Center of Kansas - Winfield
- Saint Joseph Mercy Hospital
- Michigan Cancer Research Consortium Community Clinical Oncology Program
- Oakwood Hospital
- Saint John Hospital and Medical Center
- Hurley Medical Center
- Genesys Regional Medical Center-West Flint Campus
- Allegiance Health
- Sparrow Hospital
- Saint Mary's of Michigan
- Saint John Macomb-Oakland Hospital
- Harris, John Gilbert MD (UIA Investigator)
- Medini, Eitan MD (UIA Investigator)
- Sanford Clinic North-Bemidgi
- Brainerd Medical Center Inc
- Essentia Health Saint Joseph's Medical Center
- Essentia Health Duluth Clinic CCOP
- Essentia Health Saint Mary's Medical Center
- Miller-Dwan Hospital
- Etzell, Paul S MD (UIA Investigator)
- Swenson, Wade II, MD (UIA Investigator)
- Meeker County Memorial Hospital
- Virginia Piper Cancer Institute
- Chippewa County - Montevideo Hospital
- Mayo Clinic
- CentraCare Clinic
- Saint Cloud Hospital
- Saint Joseph's Hospital - Healtheast
- Adult and Pediatric Urology PLLP
- Woodwinds Health Campus
- Montana Cancer Consortium CCOP
- Northern Rockies Radiation Oncology Center
- Saint Vincent Healthcare
- Hematology-Oncology Centers of the Northern Rockies PC
- Billings Clinic
- Deaconess Medical Center
- Bozeman Deaconess Cancer Center
- Bozeman Deaconess Hospital
- Internal Medicine of Bozeman
- Saint James Community Hospital and Cancer Treatment Center
- Saint Peter's Community Hospital
- Glacier Oncology PLLC
- Community Medical Hospital
- Montana Cancer Specialists
- Saint Patrick Hospital - Community Hospital
- Fremont Area Medical Center
- Bryan LGH Medical Center West
- Bryan LGH Medical Center East
- Saint Elizabeth Regional Medical Center
- Midlands Community Hospital
- Bismarck Cancer Center
- Mid Dakota Clinic
- Saint Alexius Medical Center
- Sanford Bismarck Medical Center
- Sanford Clinic North-Fargo
- Sanford Medical Center-Fargo
- University of Virginia
- Welch Cancer Center
Arms of the Study
Arm 1
Experimental
Treatment (erlotinib hydrochloride, radiation, temozolomide)
Patients receive oral erlotinib once daily. After 1 week of erlotinib alone, patients also receive oral temozolomide once daily for 6 weeks and undergo concurrent radiotherapy 5 days a week for 6 weeks. After completion of radiotherapy, patients continue to receive erlotinib once daily alone in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of radiotherapy, patients also receive oral temozolomide once daily for 5 days. Temozolomide treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.